ASTX727 for the Treatment of IDH Mutant Recurrent Glioma

Inclusion Criteria

• Participants must have histologically or cytologically confirmed glioma, with documented IDH1 and/or IDH2 gene-mutation
• Participants must have radiographic evidence of primarily non-enhancing disease progression/recurrence per RANO criteria for low grade gliomas (LGG). Subjects with measurable enhancing disease, defined as > 1 cm x 1 cm bi-dimensional are not eligible
• Patients who have received prior treatment with chemotherapy, radiation, or a combination of both are eligible. Also, patients who have not received any prior treatment for their glioma are also eligible
• Participants must be >= 12 weeks from completion of radiation
• Participants must have a baseline brain magnetic resonance imaging (MRI) scan within 28 days prior to day 1 of treatment
• Participants must be on a stable or decreasing dose of glucocorticoids for 7 days prior to registration
• Participants must have archived primary tumor biopsies or surgical specimens for additional exploratory translational studies. At least 100-micron length of formalin-fixed paraffin-embedded (FFPE) tissue or a tissue block should be available for enrollment and for shipment to the Sponsor, or a laboratory designated by the principal investigator. If less material is available, participants could still be eligible after discussion with the principal investigator who will assess and confirm that there is sufficient material for key evaluations
• Participants must be able to understand and willing to sign an informed consent within 6 weeks of start of treatment. A legally authorized representative may consent on behalf of a participant who is otherwise unable to provide informed consent, if acceptable to and approved by the site and/or site’s Institutional Review Board (IRB)/Independent Ethics Committee (IEC)
• Participants must have Karnofsky performance status (KPS) >= to 70
• Participants must have expected survival of >= 6 months
• Leukocytes >= 3,000/mcL
• Absolute neutrophil count >= 1500/mcL
• Hemoglobin >= 10 g/dL
• Platelets >= 100,000/mcL
• Serum total bilirubin =< 1.5 x upper limit of normal (ULN), unless considered due to Gilbert’s disease
• Aspartate aminotransferase (AST) =< 3.0 x ULN
• Alanine aminotransferase (ALT) =< 3.0 x ULN
• Alkaline phosphatase (ALP) =< 3.0 x ULN
• Serum creatinine =< 2.0 x ULN OR
• Creatinine clearance > 40 mL/min based on the Cockcroft-Gault glomerular filtration rate (GFR) estimation
• Participants must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancer. (Participants with residual grade 1 toxicity due to prior chemotherapy are allowed)
• Female participants with reproductive potential must have a negative serum pregnancy test within 14 days prior to the first study drug administration. Participants with reproductive potential are defined as sexually mature women who have not undergone a hysterectomy, bilateral oophorectomy or tubal occlusion or who have not been naturally postmenopausal (i.e., who have not menstruated at all) for at least 24 consecutive months (i.e., have had menses at any time in the preceding 24 consecutive months). Women with reproductive potential as well as fertile men and their partners who are female with reproductive potential must agree to abstain from sexual intercourse or to use 2 effective forms of contraception from the time of giving informed consent, during the study, and for 90 days (females and males) following the last dose of ASTX727
• Participants enrolling in the expansion cohort (Arm B) must meet all of the above criteria and must have surgically accessible tumors and be surgical candidates

Exclusion Criteria

• Participants with measurable enhancing disease on brain MRI defined as > 1 cm x 1 cm bi-dimensional are not eligible
• Participants who received systemic anticancer therapy < 28 days prior to registration. One exception: participants on lomustine/CCNU must wait at least 42 days from last date of drug administration to registration
• Participants who received an investigational agent < 14 days prior to registration. In addition, the first dose of ASTX727 should not occur before a period >= 5 half-lives of the investigational agent has elapsed
• Participants with prior treatment with bevacizumab (Avastin) are excluded
• Participants who are pregnant or breast-feeding
• Participants with an active severe infection that requires anti-infective therapy or with an unexplained fever > 38.5 degrees Celsius (C) during screening visits or on their first day of study drug administration
• Participants with known additional malignancy that is progressing or requires active treatment within 2 years of start of study drug. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer that has undergone potentially curative therapy, or surgically treated prostate cancer
• Participants with known hypersensitivity to any of the components of ASTX727
• Participants with a history of myocardial infarction within the 6 months prior to screening
• Participants with a known history of severe and/or uncontrolled ventricular arrhythmias
• Participants with corrected QT (QTc) interval >= 450 msec or with other factors that significantly increase the risk of QT prolongation or arrhythmic events (e.g., family history of long QT interval syndrome)
• Participants with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C
• Participants with any other medical or psychological condition, deemed by the Investigator to be likely to interfere with a participant’s ability to sign informed consent, cooperate, or participate in the study
• Participants with known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally
• Participants with evidence of intracranial or intratumoral hemorrhage either by MRI or computed tomography (CT) scan. Participants with resolving post-surgical changes, punctate/micro-hemorrhage, or hemosiderin are eligible
• Participants enrolling in the expansion cohort will be excluded is they are deemed by the treating physician or surgeon not to be suitable for surgery